1. Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's disease.
- Author
-
Opitz A, Seitz LM, Krystof V, Baselious F, Holzer M, Sippl W, and Hilgeroth A
- Subjects
- Cholinesterase Inhibitors pharmacology, Cholinesterase Inhibitors therapeutic use, Humans, Protein Kinases, tau Proteins metabolism, Alzheimer Disease metabolism
- Abstract
Background: Alzheimer's disease (AD) drugs in therapy are limited to acetylcholine esterase inhibitors and memantine. Newly developed drugs against a single target structure have an insufficient effect on symptomatic AD patients. Results: Novel aromatically anellated pyridofuranes have been evaluated for inhibition of AD-relevant protein kinases cdk1, cdk2, gsk-3b and Fyn. Best activities have been found for naphthopyridofuranes with a hydroxyl function as part of the 5-substituent and a hydrogen or halogen substituent in the 8-position. Best results in nanomolar ranges were found for benzopyridofuranes with a 6-hydroxy and a 3-alkoxy substitution or an exclusive 6-alkoxy substituent. Conclusion: First lead compounds were identified inhibiting two to three kinases in nanomolar ranges to be qualified as an innovative approach for AD multitargeting.
- Published
- 2022
- Full Text
- View/download PDF